Table 2.
Epoetin rechallenge cases (n = 34 individuals) and development of epoetin responsiveness
| Case no.* | RIPA or ELISA antibody status at rechallenge | RIPA or ELISA antibody assay | Concomitant immunosuppression | Neutralizing assay results at time of rechallenge | Epoetin responsiveness |
|---|---|---|---|---|---|
| Group 1 | |||||
| 1 | - | RIPA | + | Unknown | + |
| 2 | - | RIPA | + | - | + |
| 3 | - | RIPA | + | - | + |
| 4 | - | RIPA | - | - | + |
| 5 | - | ELISA | - | Unknown | - |
| 6 | - | ELISA | - | - | + |
| 7 | - | Unknown | + | Unknown | + |
| 8 | - | Unknown | + | Unknown | + |
| 9 | - | Unknown | - | Unknown | + |
| Group 2 | |||||
| 10 | + | RIPA | + | Unknown | - |
| 11 | + | RIPA | + | Unknown | - |
| 12 | + | RIPA | + | Unknown | - |
| 13 | + | RIPA | + | Unknown | + |
| 14 | + | RIPA | + | Unknown | + |
| 15 | + | RIPA | + | - | + |
| 16 | + | RIPA | + | - | + |
| 17 | + | ELISA | + | Unknown | - |
| 18 | + | Unknown | + | Unknown | + |
| 19 | + | Unknown | + | Unknown | + |
| 20 | + | Unknown | + | Unknown | + |
| 21 | + | Unknown | + | Unknown | - |
| 22 | + | Unknown | + | - | + |
| 23 | + | Unknown | + | + | - |
| Group 3 | |||||
| 24 | + | RIPA | - | Unknown | - |
| 25 | + | RIPA | - | Unknown | - |
| 26 | + | RIPA | - | Unknown | - |
| 27 | + | RIPA | - | Unknown | - |
| 28 | + | RIPA | - | Unknown | - |
| 29 | + | RIPA | - | Unknown | - |
| 30 | + | RIPA | - | Unknown | - |
| 31 | + | RIPA | - | Unknown | + |
| 32 | + | RIPA | - | Unknown | + |
| 33 | + | RIPA | - | - | + |
| 34 | + | ELISA | - | Unknown | - |
The 3 groups were defined as follows: Group 1, no evidence of antierythropoietin ELISA or RIPA antibody at the time of rechallenge; Group 2, antibodies detected and concomitant immunosuppression was administered; Group 3, antibodies detected and concomitant immunosuppression was not administered.
*
The percentage epoetin responsive were 89% for Group 1, 57% for Group 2, and 27% for Group 3.